首页> 美国卫生研究院文献>other >Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells
【2h】

Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells

机译:细胞毒性抗癌药物吉西他滨和EGFR酪氨酸激酶抑制剂吉非替尼通过调节NKG2D配体在非小细胞肺癌细胞中对NK细胞介导的细胞毒性的对比作用。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

IntroductionSeveral cytotoxic anticancer drugs inhibit DNA replication and/or mitosis, while EGFR tyrosine kinase inhibitors inactivate EGFR signalling in cancer cell. Both types of anticancer drugs improve the overall survival of the patients with non-small-cell lung cancer (NSCLC), although tumors often become refractory to this treatment. Despite several mechanisms by which the tumors become resistant having been described the effect of these compounds on anti-tumor immunity remains largely unknown.
机译:简介几种具有细胞毒性的抗癌药会抑制DNA复制和/或有丝分裂,而EGFR酪氨酸激酶抑制剂则会使癌细胞中的EGFR信号失活。两种类型的抗癌药物均可以改善非小细胞肺癌(NSCLC)患者的总体生存率,尽管肿瘤通常对该治疗不利。尽管已经描述了几种使肿瘤具有抗性的机制,但是这些化合物对抗肿瘤免疫的作用仍然很大程度上未知。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号